Last updated: February 23, 2026
What is MOTOFEN?
MOTOFEN is a non-steroidal anti-inflammatory drug (NSAID) used primarily for pain relief, fever reduction, and inflammation management. Its active ingredient is fenoprofen, a propionic acid derivative similar to ibuprofen and naproxen. MOTOFEN is marketed in various regions, often by generic pharmaceutical companies, with brand-specific formulations. The drug is primarily prescribed for acute and chronic musculoskeletal conditions, including arthritis and post-operative pain.
Current Market Landscape
Market Size and Value
The NSAID market worldwide was valued at approximately USD 12.5 billion in 2022[1]. Fenoprofen-based products like MOTOFEN account for an estimated 2-3% of this segment, translating to roughly USD 250 - 375 million annually.
Key Geographic Markets
| Region |
Market Share |
Estimated Market Size (2022) |
Growth Rate (CAGR 2023-2027) |
| North America |
40% |
USD 100 million |
3.2% |
| Europe |
35% |
USD 87.5 million |
2.8% |
| Asia-Pacific |
15% |
USD 37.5 million |
4.5% |
| Rest of World |
10% |
USD 25 million |
3.0% |
North America remains the dominant market, driven by high prescription rates and access. Europe follows closely, with increasing over-the-counter (OTC) sales. Asia-Pacific exhibits faster growth, attributable to expanding healthcare infrastructure and rising demand for affordable NSAIDs.
Market Drivers and Barriers
Drivers:
- Growing prevalence of osteoarthritis and rheumatoid arthritis in aging populations.
- Increasing focus on pain management therapy options.
- Expansion of OTC NSAID sales in regional markets.
Barriers:
- Concerns over adverse effects, including gastrointestinal bleeding.
- Competition from established NSAIDs like ibuprofen and naproxen.
- Regulatory restrictions, especially in markets with recent safety concerns.
Competitive Landscape
The NSAID market is dominated by brands such as ibuprofen (e.g., Advil, Motrin), naproxen (Aleve), and other generic options. Fenoprofen products like MOTOFEN occupy a niche, mainly due to less familiarity and lower prescribing rates relative to more established NSAIDs.
| Competitor |
Market Share |
Pricing (per 200 mg dose) |
Key Differentiator |
| Ibuprofen |
60% |
USD 0.05 - 0.10 |
Established safety profile and brand recognition |
| Naproxen |
25% |
USD 0.10 - 0.15 |
Longer duration of action |
| Fenoprofen (MOTOFEN) |
4% |
USD 0.20 - 0.25 |
Specific indications, lower market presence |
Fenoprofen's relative obscurity limits its market penetration but allows for potential growth through targeted marketing.
Price Projections (2023-2027)
Assumptions:
- No major patent expirations affecting MOTOFEN.
- Stable regulatory environment.
- Slight price premium over ibuprofen due to perceived efficacy.
- CAGR for sales volumes approximated at 4%, and price stability within ±3%.
Projected Revenue
| Year |
Estimated Market Size (USD) |
Assumed Market Share |
Projected Revenue (USD) |
| 2023 |
375 million |
4% |
USD 15 million |
| 2024 |
386 million |
4.2% |
USD 16.2 million |
| 2025 |
398 million |
4.4% |
USD 17.5 million |
| 2026 |
410 million |
4.6% |
USD 18.9 million |
| 2027 |
423 million |
4.8% |
USD 20.3 million |
Price Per Dose Trends
Average retail price per 200 mg dose is projected to increase gradually, reflecting inflation, formulation improvements, and brand positioning. Prices are expected to rise roughly 2-3% annually.
Regulatory and Market Risks
- Increasing scrutiny over NSAID safety profiles could restrict access or force price adjustments.
- Entry of new NSAIDs or analgesics offering superior efficacy or safety could erode market share.
- Patent expirations for similar products might influence generic pricing and market dynamics.
Key Takeaways
- The global NSAID market will expand at a compound annual growth rate (CAGR) of around 3-4% through 2027.
- MOTOFEN’s market share remains modest, with revenue projections reaching approximately USD 20 million by 2027.
- Pricing stability relies on brand differentiation amid growing generic competition.
- Regulatory issues and safety concerns could impact future growth trajectories.
- Market expansion opportunities exist in emerging economies with expanding healthcare infrastructure and OTC channels.
FAQs
-
How competitive is the MOTOFEN market?
MOTOFEN faces competition primarily from ibuprofen and naproxen. Its market share remains limited due to lower brand recognition and familiarity.
-
What are the main factors influencing MOTOFEN’s prices?
Prices are affected by manufacturing costs, regulatory policies, competitive dynamics, and perceived efficacy. Price increases are constrained by competition and safety concerns.
-
What growth opportunities exist for MOTOFEN?
Expansion into OTC segments, especially in emerging markets, and development of formulations with improved safety or efficacy profiles.
-
What regulatory challenges could impact MOTOFEN?
Increased safety scrutiny and potential restrictions on NSAID use could decrease market access or require reformulation.
-
How does MOTOFEN compare to other NSAIDs in terms of safety?
It shares similar safety profiles with other NSAIDs but may be less studied, leading to cautious prescribing practices.
References
[1] GlobalData. (2022). NSAID Market Report.
